Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001)

被引：0
|
作者：
Yokouchi, H. [1 ]
Mizugaki, H. [2 ]
Ikezawa, Y. [3 ]
Morita, R. [4 ]
Tateishi, K. [5 ]
Yokoo, K. [6 ]
Sumi, T. [7 ]
Kikuchi, H. [8 ]
Nakamura, A. [9 ]
Kobayashi, M. [10 ]
Aso, M. [11 ]
Tsukita, Y. [12 ]
Yoshiike, F. [13 ]
Furuta, M. [14 ]
Tanaka, H. [15 ]
Sekikawa, M. [16 ]
Hachiya, T. [17 ]
Nakamura, K. [18 ]
Kitamura, Y. [19 ]
机构：
[1] Hokkaido Canc Ctr, Dept Resp Med, Fukushima, Japan
[2] Japanese Fdn Canc Res, Canc Immunotherapy Dev, Adv Med Dev Ctr, Canc Inst Hosp, Koto Ku, Tokyo, Japan
[3] Oji Gen Hosp, Dept Resp Med, Tomakomai, Japan
[4] Akita Kousei Med Ctr, Thorac Oncol, Akita, Nishibukuro, Japan
[5] Shinshu Univ, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano, Japan
[6] Teine Keijinkai Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan
[7] Hakodate Goryoukaku Hosp, Dept Resp Med, Hakodate, Hokkaido, Japan
[8] JA Hokkaido Kouseiren Obihiro Kosei Gen Hosp, Dept Resp Med, Obihiro, Hokkaido, Japan
[9] Sendai Kousei Hosp, Dept Resp Med, Sendai, Miyagi, Japan
[10] Miyagi Canc Ctr, Resp Med, Natori, Miyagi, Japan
[11] Yamagata Prefectural Cent Hosp, Pulm Med, Yamagata, Japan
[12] Tohoku Univ, Dept Resp Med, Sendai, Miyagi, Japan
[13] Nagano Municipal Hosp, Dept Resp Med, Nagano, Japan
[14] Hokkaido Univ Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan
[15] Hirosaki Univ, Dept Resp Med, Hirosaki, Aomori, Japan
[16] Steel Mem Muroran Hosp, Dept Resp Med, Muroran, Hokkaido, Japan
[17] Suwa Red Cross Hosp, Dept Resp Med, Suwa, Japan
[18] Natl Hosp Org Asahikawa Med Ctr, Dept Resp Med, Asahikawa, Hokkaido, Japan
[19] Kushiro City Gen Hosp, Dept Resp Med, Kushiro, Japan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.373
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335P
引用
收藏
页码：S1574 / S1574
页数：1
相关论文
共 50 条
  • [31] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated
    Wang, Q.
    Xu, A.
    Ma, C.
    Wang, T.
    Liu, P.
    Duan, Y.
    Kong, T.
    Chen, G.
    Jia, X.
    Shang, K.
    Yang, G.
    Zhang, G.
    Yu, F.
    Wang, H.
    Chen, H.
    ANNALS OF ONCOLOGY, 2023, 34
  • [32] First-line immunotherapy in PD-L1-high non-small cell lung cancer: indirect treatment comparison of pembrolizumab and atezolizumab
    Griesinger, F.
    Sibbe, M. S.
    Hieke-Schulz, S.
    Buhck, H.
    Reinmuth, N.
    Rittmeyer, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 227 - 228
  • [33] Non-small cell Lung Cancer Atezolizumab is now also approved for First-Line Monotherapy for high PD-L1 Expression
    Vetter, Christine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (05)
  • [34] Atezolizumab in a first-line setting in non-small-cell lung cancer with high PD-L1 expression
    Dugage, Matthieu Roulleaux
    Brosseau, Solenn
    BULLETIN DU CANCER, 2021, 108 (10) : 904 - 906
  • [35] Real-world evaluation of the effectiveness and predictive factors of anti-PD-1/PD-L1 inhibitors as the first-line therapy for metastatic non-small cell lung cancer
    Chen, Jing
    Yang, Dingyi
    Lei, Qianqian
    Long, Yanyan
    ASIAN JOURNAL OF SURGERY, 2023, 46 (09) : 4103 - 4104
  • [36] Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
    Banna, Giuseppe Luigi
    Signorelli, Diego
    Metro, Giulio
    Galetta, Domenico
    Toma, Alessandro De
    Cantale, Ornella
    Banini, Marco
    Friedlaender, Alex
    Pizzutillo, Pamela
    Garassino, Marina Chiara
    Addeo, Alfredo
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1533 - +
  • [37] First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study
    Amrane, Karim
    Geier, Margaux
    Corre, Romain
    Lena, Herve
    Leveiller, Guillaume
    Gadby, Florence
    Lamy, Regine
    Bizec, Jean-Louis
    Goarant, Eric
    Robinet, Gilles
    Gouva, Sylvie
    Quere, Gilles
    Abgral, Ronan
    Schick, Ulrike
    Bernier, Cyril
    Chouaid, Christos
    Descourt, Renaud
    CANCER MEDICINE, 2020, 9 (07): : 2309 - 2316
  • [38] PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
    Isla, Dolores
    Sanchez, Alfredo
    Casal, Joaquin
    Cobo, Manuel
    Majem, Margarita
    Reguart, Noemi
    Zugazagoitia, Jon
    Bernabe, Reyes
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [39] Time on Treatment of First-Line PD-1 Inhibitor Monotherapy for Metastatic Non-Small Cell Lung Cancer Patients: Real-World Experience Data
    Apter, L.
    Moser, S. Sharman
    Chandwani, S.
    Chen, X.
    Shalev, V.
    Chodick, G.
    Siegelmann-Danieli, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S920 - S920
  • [40] Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy
    Ge, Wenzhen
    Wu, Ning
    Jalbert, Jessica J.
    Quek, Ruben G. W.
    Liu, Jinjie
    Rietschel, Petra
    Pouliot, Jean-Francois
    Harnett, James
    Hsu, Melinda Laine
    Feliciano, Josephine L.
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 3191 - 3202
12345